New hope for arthritis sufferers: experimental drug CND261 enters human trials
NCT ID NCT07052032
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This early-stage study tests a new drug called CND261 in 47 adults with moderate-to-severe rheumatoid arthritis who haven't responded well to other treatments. The main goal is to check the drug's safety and how the body handles it. Researchers will also look for signs that the drug might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Candid Clinical Site
Tbilisi, Georgia
-
Candid Clinical Site
Chisinau, Moldova
-
Candid Clinical Site
Kyiv, Ukraine
Conditions
Explore the condition pages connected to this study.